$CRVO News
Last published 2d ago
- 2d agoCRVOCervoMed Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoCRVOCervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswirePresentation and publication of clinical and biomarker data, regulatory developments, and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies
- 3d agoCRVOCervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswirePresentation and publication of clinical and biomarker data, regulatory developments, and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies
- 2w agoCRVOCervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)GlobeNewswirePlacebo-controlled results of RewinD-LB clinical trial published in Alzheimer’s Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB
- 1mo agoCRVOCervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026GlobeNewswireOn average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median 24-week biomarker data
- 2mo agoCRVOCervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026GlobeNewswire12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology,
- 2mo agoCRVOCervoMed to Participate in September Investor ConferencesGlobeNewswireBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today
- 3mo agoCRVOCervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswirePrioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative
- 3mo agoCRVOCervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireBOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that
- 3mo agoCRVOCervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)GlobeNewswireInnovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines Neflamapimod selected for the ILAP by joint
- 4mo agoCRVOCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)GlobeNewswireBOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase
- 4mo agoCRVOCervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal DementiaGlobeNewswireInterim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a
- 4mo agoCRVOCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026GlobeNewswireLatest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as
- 4mo agoCRVOCervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesGlobeNewswireBOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the
- 4mo agoCRVOCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesGlobeNewswireBOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has
- 4mo agoCRVOCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042GlobeNewswireBOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has
- 4mo agoCRVONTHISPCXWULFWall Street Chases the Next Big BreakoutGlobeNewswireDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As Wall Street increasingly rewards companies with differentiated technologies and clearly defined growth catalysts, here are four names that have emerged
- 4mo agoCRVOEWTXNTHISLBTBiotech Bulls Stampede as Clinical Wins and Milestones Fuel MomentumGlobeNewswireDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell
- 5mo agoCRVOCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitGlobeNewswireBOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that
- 5mo agoCRVOCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy BodiesGlobeNewswireAdditional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies Anticipated pipeline
- 5mo agoCRVOCervoMed Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireContinued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing Presented new analyses at AAN 2026 highlighting
- 6mo agoCRVOCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy BodiesGlobeNewswireResults consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate with previously
- 7mo agoCRVOCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual MeetingGlobeNewswireUpdate will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will also be featured at
- 8mo agoCRVOCervoMed to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will
- 8mo agoCRVOCervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy BodiesGlobeNewswireBioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of
- 8mo agoCRVOCervoMed's neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral SclerosisGlobeNewswireNeflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first
- 8mo agoCEROCRVOSCYXCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel
- 11mo agoCRVOCervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy BodiesGlobeNewswirePhase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated
- 11mo agoCRVOCervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)GlobeNewswire1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions
- 11mo agoCRVOCervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswireLate-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating the utility of
- 1y agoCRVOCervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireAligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial
- 1y agoCRVOCervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy BodiesGlobeNewswireFDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is advancing preparations
- 1y agoCRVOCervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David QuigleyGlobeNewswireMr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial
- 1y agoCRVOCervoMed to Present at the Emerging Growth ConferenceGlobeNewswireBOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that
- 1y agoCRVOCervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy BodiesGlobeNewswireSignificant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having
- 1y agoCRVOCervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business OfficerGlobeNewswireBOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the
- 1y agoCRVOCervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireBOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that
- 1y agoCRVOCervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association ConferenceGlobeNewswireBOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the
- 1y agoCRVOCervoMed to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will
- 1y agoCRVOCervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireReported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which
- 1y agoCRVOCervoMed to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireBOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will
- 1y agoCRVOCervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of NeurodegenerationGlobeNewswireBased on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of
- 1y agoCRVOCervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025GlobeNewswireCompany to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to
- 1y agoCRVOCervoMed Announces New Hire to Support Neflamapimod Development and CommercializationGlobeNewswireStrengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10,
- 1y agoCRVOCervoMed Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireReported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate
- 1y agoCRVOCervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor ConferenceGlobeNewswireBOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that
- 1y agoCRVOInvestigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025GlobeNewswireDuring the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical
- 1y agoCRVOCervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)GlobeNewswireBOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral
- 1y agoCRVOCervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial's primary outcome measure- -Plan
- 1y agoCRVOCervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy BodiesGlobeNewswireA new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in